May 31, 2018
Vericel (VCEL) proposes 5 M share $65 M offering at $13.00
May 16, 2018
Verastem Oncology (VSTM) proposes $35 M offering priced at $4.50 - SELL
May 9, 2018
AxoGen (AXGN) now proposes a 3 M share offering priced at $41.00 - SELL
April 26, 2018
Sangamo Therapeutics (SGMO) prices $200 M offering at $16.25 - SELL
April 9, 2018
Novartis (NVS) to acquire gene therapy company AveXis (AVXS) for $218 per share in a $8.7 billion deal
April 4, 2018
Cellectis (CLLS) prices follow-on $175 M ADS offering
April 3, 2018
Cellectis (CLLS) and Allogene Therapeutics accelerate allogeneic off-the-shelf CAR T Therapies
April 2, 2018
RegMed Investors’ (RMi) motto: Worried about in 2018 (?), think eight (8) factors…
March 28, 2018
bluebird bio (BLUE)and Celgene (CELG) ink agreement to co-develop/promote Anti-BCMA CAR T cell therapy (bb2121) in the US
March 19, 2018
Fate Therapeutics (FATE) dished additional safety data from P1 Stage of PROTECT Clinical Trial of ProTmune™
March 13, 2018
Athersys (ATHX) and HEALIOS K.K. Binding letter of intent to expand MultiStem® Collaboration
March 4, 2018
RegMed Investors’ (RMi) wrapping-up January and February while determining March’s strength …
February 26, 2018
RegMed Investors’ (RMi) motto: Worried about in 2018 (?), think eight (8) factors …
February 7, 2018
Adverum Biotechnologies (ADVM) closed $69 M offering
February 6, 2018
RegMed Investors’ (RMi) motto: Worried about in 2018 (?), think five (5) things …
January 30, 2018
Bellicum Pharmaceuticals (BLCM) takes a big hit as FDA imposes clinical hold on BPX-501
January 26, 2018
Verastem (VSTM) presents pre-clinical data of Duvelisib in combination with co-stimulatory antibodies in a B Cell Lymphoma Model
January 24, 2018
Spark Therapeutics (ONCE) and Novartis (NVS) enter into a Licensing/Supply Agreement with upfront fee of $105 M
January 22, 2018
Histogenics Corporation (HSGX) Prices Registered Direct Offering (RDO) of 2,340,430 shares at $2.35
January 22, 2018
Stemline Therapeutics (STML) proposes 3.7 M share offering
January 16, 2018
Intrexon (XON) Prices 6 M share offering at $12.50
January 16, 2018
Capricor (CAPR) Licenses additional patent applications from Cedars-Sinai Medical Center (CSMC) for cellular and exosome-based technologies
January 12, 2018
AquaBounty Technologies (AQB) 3.69 M share, $12 M offering priced at $3.25
January 9, 2018
Histogenics Corporation (HSGX), Receipt of $10 Million Up-front Payment for Japanese Neocart Agreement
January 5, 2018
Takeda Pharmaceutical intents to acquire TiGenix (Brussels and NASDAQ: TIG)
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.